Title of Invention	"A REFERENCE COMPOUND FOR USE IN THE ANALYSIS OF LEVOSIMEDAN BATCHES"
Abstract	The present invention relaes to a pyndazinyl derivative (I) and use as a reference compound in the Jetermination of potentially genotoxic impurities in levosimendan samples. The invention also relates to an analytic method for the determintion of potentially genotoxic impurities in levosimendan samples wherein (I) is used as a reference compound. Levosimendan is a medicanent useful in the treatment of heart failure.

Title of Invention

"A REFERENCE COMPOUND FOR USE IN THE ANALYSIS OF LEVOSIMEDAN BATCHES"

Abstract

The present invention relaes to a pyndazinyl derivative (I) and use as a reference compound in the Jetermination of potentially genotoxic impurities in levosimendan samples. The invention also relates to an analytic method for the determintion of potentially genotoxic impurities in levosimendan samples wherein (I) is used as a reference compound. Levosimendan is a medicanent useful in the treatment of heart failure.

Full Text	1 A REFERENCE COMPOUND FOR USE IN THE ANALYSIS OF LEVOSIMENDAN BATCHES Background of the invention The present invention relates to [[4-(2-azido-3-methyl-5-oxotetrahydrofuran-2-yl)phenyl]hydrazono]propanedinitrile (I) and its use as a reference compound in the analysis of batches of levosimendan synthesis, particularly in the determination of potentially genotoxic impurities in samples of a levosimendan batch. The present invention also relates to an analytic method for the determination of potentially genotoxic impurities in samples of a levosimendan batch wherein [[4-(2-azido-3-methyl-5-oxotetrahydrofuran-2-yl)phenyl]hydrazono ] propanedinitrile (I) is used as a reference compound. Levosimendan, which is the (-)-enantiomer of [[4-(l,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile, and the method for its preparation is described e.g. in EP 565546 Bl. Levosimendan is potent in the treatment of heart failure and has significant calcium dependent binding to troponin. The use of levosimendan in the treatment of myocardial ischemia is described in WO 93/21921. The hemodynamic effects of levosimendan in man are described in Sundberg, S. et at, Am. J. Cardiol., 1995; 75: 1061-1066. Levosimendan is represented by the formula: Clinical studies have confirmed the beneficial effects of levosimendan in heart failure patients. Levosimendan can be prepared in high purity and in nearly quantitative yields by treating (-)-6-(4-aminophenyl)-5-methyl-4,5- 2 Summary of the invention It has now been found that the potential genotoxic properties of fevosimendan samples are caused by an azido derivative impurity of formula (I) This azido derivative is a potent matagen which can be formed curing levosimendan synthesis in an amount suff.;ient to give a positive result in the bacterial rmr.agenity test. This compound named [[4-(2-azido-3-methyI-5-oxotetrahydrofuran-2-yl)phcnyl]hydrazonc]propanedinitrilc (I) is therefore useful as a reference compound in the routine analysis of batches of levosimenda:. synthesis, particularly in the determination of potentially genotoxic impurities in levosimendan batches. The presence of (I) in a levosimer.dan batch indicates that further recrystallization is necessary for obtaining ievosimendan material suitable for use as a medicine. Brief description of the drawings FIG. 1 is a HPLC-chromatogram o: the [[4-(2-azido-3-methyl-5-oxotetrahydrofuran-2-yl)phenyI]hydrazono]propanedinitrilc standard (0.- g/ml). FIG. 2 is a HPLC-chromatogram o: levosimendan raw material. Detailed description of the invention The present invention provides a reference compound having structure (I) for the determination of potentially genotoxic impurities in samples of a levosimendan batch. The present invention also provides a reference preparation for the determination of potentially genotoxic impurities in samples of a levosirnendan batch comprising compound (I) optionally together with an analytically acceptable carrier, and in particular essentially in the absence of pyridazinyl derivatives. 3 The present invention also provides the use of (I) as a reference compound in the determination of potentially genotoxic impurities in samples of a levosimendan batch. The present invention also provides an analytic method for the determination of potentially genotoxic impurities in samples of a levosimendan batch characterized in that compound (I) is used as a reference compound, particularly as said levosimendan sample is analyzed by High Pressure Liquid Chromatography (HPLC). Furthermore, the present invention provides an analytic method for the determination of potentially genotoxic impurities in samples of a levosimendan batch which method comprises preparing a reference standard solution by dissolving compound (I) in solution, preparing a test solution by dissolving a sample of a levosimendan batch in solution, obtaining a HPLC chromatogram of said reference standard solution, obtaining a HPLC chromatogram of said test solution and determining the concentration of compound (I) in the sample. The term "analytically acceptable carrier" means here a carrier which does not hamper the qualitative or quantitative analysis of (I). The selection of a suitable analytically acceptable carrier is well known to one skilled in the an. An example of an analytically acceptable carrier is dimethyl sulphoxide. Compound (I) can be prepared by treating 6-(4-aminophenyl)-5-methyl-4,5-dihydro-3(2H)-pyridazinone with sodium nitrite and malononitriie wherein sodium nitrite is used in molar excess and separating (I) from the reaction mixture. The procedure is described in detail in Example 1. The product of a levosimendan batch is preferably analyzed using High Pressure Liquid Chromatography (HPLC). Suitable apparatus include e.g. C-8 reversed phase HPLC column with UV-detection at 360 nm. The mobile phase is e.g. a mixture of phosphate buffer pH 2.1 and acetonitrile. The levosimendan sample is dissolved in suitable solvent such as a mixture of dimethyl sulfoxide, methanol and water. The reference solutions are prepared by dissolving compound (I) in suitable solvent. The retention times of levosimendan and compound (I) or diastereomers thereof are determined in the chromatographic conditions used. The amount of (I) in the levosimendan sample is determined by comparing the chromatograms obtained for the sample solution and the reference solution. The procedure is described in detail in Example 2. 4 The amount of the undssired impurity (I) in a levosimendan batch can be reduced by methods known in the art such as recrystallizatioa. Recrystallization of levosimendan can be performed from any suitable solvent acetone being the preferred solvent. EXAMPLES Example 1. Preparation of [[4-(2-azido-3-methyl-5-oiotetrahydro-furan-2-yl)phenyl]hydrazono]propanetinitrile (mixture of diastereomers) 6-(4-Aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone (153 g, 0.75 mol) was dissolved in acetic acid (750 mL). Solid sodium mirite (210 g, 3,0 mol) was slowly added to the solution at 10 - 20 °C. After the addition the mixture was stirred for 90 min at 10 - 20 °C The reaction mixture was poured rapidly to a 20 °C solution of malononitrile (150g, 2.3 mol) and water( 1500 nL). The resulting aiixture was stirred at 20-25 °C for 60 min and then filtered aid washed with water. The wet solid was extracted successively with tetrahydrofurn (300 mL) and ethyl acetate (1900 mL). The combined extracts were dried with sodium sulphate and the solvents evaporated under vacaum. The residue was triturated with ethyl acetate (200 mL), filtered and the filtrate was evaporated under vacuum. The residue (8,0 g) was purified cromatographically on silica gel using toluene-ethyl acetate 2:1 as the eluent. After crystallization from toluene the yield of pure mixture of diastereomers was 1,0 g. The major component of the mixture can be enriched by multiple crystallizations from toluene, rut for analytical purposes the mixture is adequate. iH-NMR (400MHz, DMSO-d5 a) major diastereomer 1.06 d, 3H, J=6Hz), 2,55 (dd, 1H, J=16 Hz, 11 Hz), 2.67 (m, 1H), 2.78 (dd, 1H, J=16 Hz, 8 Hz), 7.59 (d, 1H, J= 9Hz), 7.62 (d, 1H, J= 9Hz), 12.6 (broad s, 1H), minor diastereomer 0.60 (d, 3H, J=7 Hz), 2,43 (dd, 1H, J=18 Hz, 2 Hz), 2.78 (m, 1H), 3.14 (dd, 1H, J=8 Hz, 18 Hz), 7.54 (d,lH, J=9 Hz), 7.61(d,lEJ=9 Hz), 12.6 (broad s, 1H). Example 2. Use of [[4-(2-azido-3-methyl-5-oxotetrahydro-furan-2-yl)phenyl]hydrazono]propanecinitrile (I) as a reference compound in HPLC-chromatography The HPLC (High Pressure Liquid Chromatography) method for analysis of compound (I) in levosimendan raw material was based on the C-8 reversed phase HPLC column with UV-detecton at 360 nm. The mobile phsse consisted of acetonitrile and phosphate buffer pH 2.1. 5 Reagents: 1. Methanol, HPLC grade 2. Sodium dihydrogen phosphate, NaH2PO4 x H2O, Merck 3. Ortho phosphoric acid, H3PO4, Merck 4. Phosphate buffer pH 2.1; Dissolve 1.8 g of sodium dihydrogen phosphate (NaH2PO4) in water and add 2.0 ml of phosphoric acid. Adjust the pH if necessary with 2 M sodium hydroxide or 1 M phosphoric acid. Dilute to 1000.0 ml with water. 5. Dimethyl sulphoxide, BDH 6. Acetonitrile, HPLC grade 7. Solvent: Mix 200 ml of methanol with 800 ml of water 8. [[4-(2-azido-3-methyl-5-oxotetrahydro-furan~2-yI)phenyl]hydrazono]- propanedinitrile reference standard Standard solutions (reference preparations of compound (I)): Stock solution: 10.00 mg of [[4-(2-azido-3-methyl-5-oxotetrahydro-furan-2- yl)phenyl]hydrazono]propanedinitrile is dissolved in a 100 ml volumetric flask in 20 ml of dimethyl sulphoxide and filled to volume with methanol. Standard solution 1 (50 ug/ml): 5.00 ml of the stock solution is diluted to 10.0 ml with solvent. Standard solution:2 (0.4 g/ml = 40 ppm): 1.00 ml of the stock solution is diluted to 250.0 ml with solvent. Quantitation limit solution (0.1 g/ml = 10 ppm); 5.00 ml of standard solution 2 is diluted to 20.0 ml solvent. Test solution 100 mg of test sample is dissolved in a 10 ml volumetric flask in 8 ml of dimethyl sulphoxide and filled to volume with solvent. Chromatographic conditions: Apparatus Liquid chromatograph Detector UV-VIS, detection wavelength 360 nm Column Symmetry C 8,3.0 jim, 7.5 cm x 4.6 mm Oven temperature ambient Mobile phase A: phosphate buffer pH 2.1 6 B: acetonitrile %B 0 min20% 5 min 30 % 15 min 30 % 30 min 90 % Flow rate 0.8 ml/min Injection volume 100 l Run time 30 min Post time 10 min Retention times: levosimendan about 13 min Compound (I) minor diastereomer: about 24 min Compound (I) major diastereomer: about 25 min System suitability 1. Replicate injections of quantitation limit solutions must be repeatable; 6 injections, RSD = 10.0%. Procedure After the system suitability criteria are met, proceed with the standard and sample injections. Calculations The concentration of the major diastereomer of compound (I) in ppm will be calculated according to the following equation: Ca = concentration of the major diastereomer of compound (I) in [[4-(2-azido-3-mcthyl-5-oxotetrahydro-furan-2-yl)phenyl]hydrazono]propane-dinitrile standard solution (mg/ml) Rx = the peak area of the major diastereomer of compound (I) in the chromatogram of the test solution Ra = the peak area of the major diastereomer of compound (I) in the chromatogram of the [[4-(2-azido-3-methyl-5-oxotetrahydro-furan-2-yl)-phenyl3hydrazono]propanedinitrile standard solution w = weight of the sample 10 = dilution factor of the sample (ml) 7 The concentration of the minor diastereomer of compound (I) in ppm will be calculated according to the following equation. The major diastereomer of compound (I) is used as a reference standard. C51 = concentration of the minor diastereomer of compound (I) in [[4-(2-azido-3-methyl-5-oxotetrahydro-furan-2-yl)phenyl]hydrazono]propane-dinitrile standard solution (mg/ml) Rx = the peak area of the minor diastereomer of compound (I) in the chromatogram of the test solution Rst = the peak area of the minor diastereomer of compound (I) in the chromatogram of the [[4-(2-azido-3-methyl-5-oxotetrahydro-furan-2-yl)-phenyl]hydrazono]propanedinitrile standard solution w = weight of the sample 10 = dilution factor of the sample (ml) 1.023 = correction factor for the minor diastcrcomer of compound (I) The chromatogram of the [[4-(2-azido-3-mcthyl-5-oxotetrahydro-furan-2-yl)phenyl]hydrazono]propanedinitrile standard (0.4 ug/ml) obtained is shown in Figure 1. The retention time for the major diastereomer of compound (I) is 25.180 min and for the minor diastereomer of compound (I) 24.866 min. The chromatogram of levosimendan raw material is shown in Figure 2. 8 WE CLAIM : 1. A compound characterized by having the structure of formula I Q and diastereomers thereof. 2. A reference preparation for the determination of potentially genotoxic impurities in samples of a levosimendan batch comprising compound as claimed in claim 1. 3. A preparation as claimed in claim 2, essentially in the absence of pyridazinyl compounds. 4. A reference preparation for the determination of potentially genotoxic impurities in samples of a levosimendan batch comprising compound as claimed in claiml together with an analytically acceptable carrier. 5. A preparation as claimed in claim 4, essentially in the absence of pyridazinyl compounds. 6. A compound as claimed in claiml, capable of being used as a reference compound in the determination of potentially genotoxic impurities in samples of a levosimendan batch. 7. An analytic method for the determination of potentially genotoxic impurities in samples of a levosimendan batch characterized in that compund as claimed in claim 1 is used as a reference compound. 8. A method as claimed in claim 7, characterized in that a sample of a levosimendan batch is analyzed by High Pressure Liquid Chromatography (HPLC). 9 9. An analytic method for the determination of potentially genotoxic impurities in samples of a levosimendan batch which method comprises preparing a reference standard solution by dissolving compound as claimed in claim 1 in solution, preparing a test solution by dissolving a sample of a levosimendan batch in solution, obtaining a HPLC chromatogram of said reference standard solution, obtaining a HPLC chromatogram of said test solution and determining the concentration of compound as claimed in claim 1 in the sample. The present invention relaes to a pyndazinyl derivative (I) and use as a reference compound in the Jetermination of potentially genotoxic impurities in levosimendan samples. The invention also relates to an analytic method for the determintion of potentially genotoxic impurities in levosimendan samples wherein (I) is used as a reference compound. Levosimendan is a medicanent useful in the treatment of heart failure.

Full Text

1
A REFERENCE COMPOUND FOR USE IN THE ANALYSIS OF LEVOSIMENDAN BATCHES
Background of the invention
The present invention relates to [[4-(2-azido-3-methyl-5-oxotetrahydrofuran-2-yl)phenyl]hydrazono]propanedinitrile (I) and its use as a reference compound in the analysis of batches of levosimendan synthesis, particularly in the determination of potentially genotoxic impurities in samples of a levosimendan batch. The present invention also relates to an analytic method for the determination of potentially genotoxic impurities in samples of a levosimendan batch wherein [[4-(2-azido-3-methyl-5-oxotetrahydrofuran-2-yl)phenyl]hydrazono ] propanedinitrile (I) is used as a reference compound.
Levosimendan, which is the (-)-enantiomer of [[4-(l,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile, and the method for its preparation is described e.g. in EP 565546 Bl. Levosimendan is potent in the treatment of heart failure and has significant calcium dependent binding to troponin. The use of levosimendan in the treatment of myocardial ischemia is described in WO 93/21921. The hemodynamic effects of levosimendan in man are described in Sundberg, S. et at, Am. J. Cardiol., 1995; 75: 1061-1066. Levosimendan is represented by the formula:

Clinical studies have confirmed the beneficial effects of levosimendan in heart failure patients.
Levosimendan can be prepared in high purity and in nearly quantitative yields by treating (-)-6-(4-aminophenyl)-5-methyl-4,5-
2
Summary of the invention
It has now been found that the potential genotoxic properties of fevosimendan samples are caused by an azido derivative impurity of formula (I)

This azido derivative is a potent matagen which can be formed curing levosimendan synthesis in an amount suff.;ient to give a positive result in the bacterial rmr.agenity test. This compound named [[4-(2-azido-3-methyI-5-oxotetrahydrofuran-2-yl)phcnyl]hydrazonc]propanedinitrilc (I) is therefore useful as a reference compound in the routine analysis of batches of levosimenda:. synthesis, particularly in the determination of potentially genotoxic impurities in levosimendan batches. The presence of (I) in a levosimer.dan batch indicates that further recrystallization is necessary for obtaining ievosimendan material suitable for use as a medicine.
Brief description of the drawings
FIG. 1 is a HPLC-chromatogram o: the [[4-(2-azido-3-methyl-5-oxotetrahydrofuran-2-yl)phenyI]hydrazono]propanedinitrilc standard (0.- g/ml).
FIG. 2 is a HPLC-chromatogram o: levosimendan raw material. Detailed description of the invention
The present invention provides a reference compound having structure (I) for the determination of potentially genotoxic impurities in samples of a levosimendan batch. The present invention also provides a reference preparation for the determination of potentially genotoxic impurities in samples of a levosirnendan batch comprising compound (I) optionally together with an analytically acceptable carrier, and in particular essentially in the absence of pyridazinyl derivatives.

3
The present invention also provides the use of (I) as a reference compound in the determination of potentially genotoxic impurities in samples of a levosimendan batch.
The present invention also provides an analytic method for the determination of potentially genotoxic impurities in samples of a levosimendan batch characterized in that compound (I) is used as a reference compound, particularly as said levosimendan sample is analyzed by High Pressure Liquid Chromatography (HPLC).
Furthermore, the present invention provides an analytic method for the determination of potentially genotoxic impurities in samples of a levosimendan batch which method comprises preparing a reference standard solution by dissolving compound (I) in solution, preparing a test solution by dissolving a sample of a levosimendan batch in solution, obtaining a HPLC chromatogram of said reference standard solution, obtaining a HPLC chromatogram of said test solution and determining the concentration of compound (I) in the sample.
The term "analytically acceptable carrier" means here a carrier which does not hamper the qualitative or quantitative analysis of (I). The selection of a suitable analytically acceptable carrier is well known to one skilled in the an. An example of an analytically acceptable carrier is dimethyl sulphoxide.
Compound (I) can be prepared by treating 6-(4-aminophenyl)-5-methyl-4,5-dihydro-3(2H)-pyridazinone with sodium nitrite and malononitriie wherein sodium nitrite is used in molar excess and separating (I) from the reaction mixture. The procedure is described in detail in Example 1.
The product of a levosimendan batch is preferably analyzed using High Pressure Liquid Chromatography (HPLC). Suitable apparatus include e.g. C-8 reversed phase HPLC column with UV-detection at 360 nm. The mobile phase is e.g. a mixture of phosphate buffer pH 2.1 and acetonitrile. The levosimendan sample is dissolved in suitable solvent such as a mixture of dimethyl sulfoxide, methanol and water. The reference solutions are prepared by dissolving compound (I) in suitable solvent. The retention times of levosimendan and compound (I) or diastereomers thereof are determined in the chromatographic conditions used. The amount of (I) in the levosimendan sample is determined by comparing the chromatograms obtained for the sample solution and the reference solution. The procedure is described in detail in Example 2.

4
The amount of the undssired impurity (I) in a levosimendan batch can be reduced by methods known in the art such as recrystallizatioa. Recrystallization of levosimendan can be performed from any suitable solvent acetone being the preferred solvent.
EXAMPLES
Example 1. Preparation of [[4-(2-azido-3-methyl-5-oiotetrahydro-furan-2-yl)phenyl]hydrazono]propanetinitrile (mixture of diastereomers)
6-(4-Aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone (153 g, 0.75 mol) was dissolved in acetic acid (750 mL). Solid sodium mirite (210 g, 3,0 mol) was slowly added to the solution at 10 - 20 °C. After the addition the mixture was stirred for 90 min at 10 - 20 °C The reaction mixture was poured rapidly to a 20 °C solution of malononitrile (150g, 2.3 mol) and water( 1500 nL). The resulting aiixture was stirred at 20-25 °C for 60 min and then filtered aid washed with water. The wet solid was extracted successively with tetrahydrofurn (300 mL) and ethyl acetate (1900 mL). The combined extracts were dried with sodium sulphate and the solvents evaporated under vacaum. The residue was triturated with ethyl acetate (200 mL), filtered and the filtrate was evaporated under vacuum. The residue (8,0 g) was purified cromatographically on silica gel using toluene-ethyl acetate 2:1 as the eluent. After crystallization from toluene the yield of pure mixture of diastereomers was 1,0 g. The major component of the mixture can be enriched by multiple
crystallizations from toluene, rut for analytical purposes the mixture is adequate. iH-NMR (400MHz, DMSO-d5 a) major diastereomer 1.06 d, 3H, J=6Hz), 2,55
(dd, 1H, J=16 Hz, 11 Hz), 2.67 (m, 1H), 2.78 (dd, 1H, J=16 Hz, 8 Hz), 7.59 (d, 1H, J= 9Hz), 7.62 (d, 1H, J= 9Hz), 12.6 (broad s, 1H), minor diastereomer 0.60 (d, 3H, J=7 Hz), 2,43 (dd, 1H, J=18 Hz, 2 Hz), 2.78 (m, 1H), 3.14 (dd, 1H, J=8 Hz, 18 Hz), 7.54 (d,lH, J=9 Hz), 7.61(d,lEJ=9 Hz), 12.6 (broad s, 1H).
Example 2. Use of [[4-(2-azido-3-methyl-5-oxotetrahydro-furan-2-yl)phenyl]hydrazono]propanecinitrile (I) as a reference compound in HPLC-chromatography
The HPLC (High Pressure Liquid Chromatography) method for analysis of compound (I) in levosimendan raw material was based on the C-8 reversed phase HPLC column with UV-detecton at 360 nm. The mobile phsse consisted of acetonitrile and phosphate buffer pH 2.1.

5
Reagents:
1. Methanol, HPLC grade
2. Sodium dihydrogen phosphate, NaH2PO4 x H2O, Merck
3. Ortho phosphoric acid, H3PO4, Merck
4. Phosphate buffer pH 2.1;
Dissolve 1.8 g of sodium dihydrogen phosphate (NaH2PO4) in water and add 2.0 ml
of phosphoric acid. Adjust the pH if necessary with 2 M sodium hydroxide or 1 M phosphoric acid. Dilute to 1000.0 ml with water.
5. Dimethyl sulphoxide, BDH
6. Acetonitrile, HPLC grade
7. Solvent: Mix 200 ml of methanol with 800 ml of water
8. [[4-(2-azido-3-methyl-5-oxotetrahydro-furan~2-yI)phenyl]hydrazono]-
propanedinitrile reference standard
Standard solutions (reference preparations of compound (I)):
Stock solution: 10.00 mg of [[4-(2-azido-3-methyl-5-oxotetrahydro-furan-2-
yl)phenyl]hydrazono]propanedinitrile is dissolved in a 100 ml volumetric flask in 20
ml of dimethyl sulphoxide and filled to volume with methanol.
Standard solution 1 (50 ug/ml): 5.00 ml of the stock solution is diluted to 10.0 ml
with solvent.
Standard solution:2 (0.4 g/ml = 40 ppm): 1.00 ml of the stock solution is diluted to
250.0 ml with solvent.
Quantitation limit solution (0.1 g/ml = 10 ppm); 5.00 ml of standard solution 2 is
diluted to 20.0 ml solvent.
Test solution
100 mg of test sample is dissolved in a 10 ml volumetric flask in 8 ml of dimethyl sulphoxide and filled to volume with solvent.
Chromatographic conditions:
Apparatus Liquid chromatograph
Detector UV-VIS, detection wavelength 360 nm
Column Symmetry C 8,3.0 jim, 7.5 cm x 4.6 mm
Oven temperature ambient
Mobile phase A: phosphate buffer pH 2.1

6
B: acetonitrile
%B 0 min20%
5 min 30 %
15 min 30 %
30 min 90 %
Flow rate 0.8 ml/min
Injection volume 100 l
Run time 30 min
Post time 10 min
Retention times: levosimendan about 13 min
Compound (I) minor diastereomer: about 24 min
Compound (I) major diastereomer: about 25 min
System suitability
1. Replicate injections of quantitation limit solutions must be repeatable;
6 injections, RSD = 10.0%.
Procedure
After the system suitability criteria are met, proceed with the standard and sample injections.
Calculations
The concentration of the major diastereomer of compound (I) in ppm will be calculated according to the following equation:

Ca = concentration of the major diastereomer of compound (I) in [[4-(2-azido-3-mcthyl-5-oxotetrahydro-furan-2-yl)phenyl]hydrazono]propane-dinitrile standard solution (mg/ml)
Rx = the peak area of the major diastereomer of compound (I) in the chromatogram of the test solution
Ra = the peak area of the major diastereomer of compound (I) in the
chromatogram of the [[4-(2-azido-3-methyl-5-oxotetrahydro-furan-2-yl)-phenyl3hydrazono]propanedinitrile standard solution
w = weight of the sample
10 = dilution factor of the sample (ml)

7
The concentration of the minor diastereomer of compound (I) in ppm will be calculated according to the following equation. The major diastereomer of compound (I) is used as a reference standard.

C51 = concentration of the minor diastereomer of compound (I) in [[4-(2-azido-3-methyl-5-oxotetrahydro-furan-2-yl)phenyl]hydrazono]propane-dinitrile standard solution (mg/ml)
Rx = the peak area of the minor diastereomer of compound (I) in the chromatogram of the test solution
Rst = the peak area of the minor diastereomer of compound (I) in the
chromatogram of the [[4-(2-azido-3-methyl-5-oxotetrahydro-furan-2-yl)-phenyl]hydrazono]propanedinitrile standard solution
w = weight of the sample
10 = dilution factor of the sample (ml)
1.023 = correction factor for the minor diastcrcomer of compound (I)
The chromatogram of the [[4-(2-azido-3-mcthyl-5-oxotetrahydro-furan-2-yl)phenyl]hydrazono]propanedinitrile standard (0.4 ug/ml) obtained is shown in Figure 1. The retention time for the major diastereomer of compound (I) is 25.180 min and for the minor diastereomer of compound (I) 24.866 min. The chromatogram of levosimendan raw material is shown in Figure 2.

8
WE CLAIM :

1.

A compound characterized by having the structure of formula I Q

and diastereomers thereof.
2. A reference preparation for the determination of potentially genotoxic impurities in
samples of a levosimendan batch comprising compound as claimed in claim 1.
3. A preparation as claimed in claim 2, essentially in the absence of pyridazinyl compounds.
4. A reference preparation for the determination of potentially genotoxic impurities
in samples of a levosimendan batch comprising compound as claimed in claiml together with an analytically acceptable carrier.
5. A preparation as claimed in claim 4, essentially in the absence of pyridazinyl compounds.
6. A compound as claimed in claiml, capable of being used as a reference compound
in the determination of potentially genotoxic impurities in samples of a
levosimendan batch.
7. An analytic method for the determination of potentially genotoxic impurities in
samples of a levosimendan batch characterized in that compund as claimed in claim 1
is used as a reference compound.
8. A method as claimed in claim 7, characterized in that a sample of a levosimendan batch is analyzed by High Pressure Liquid Chromatography (HPLC).

9
9. An analytic method for the determination of potentially genotoxic impurities in samples of a levosimendan batch which method comprises preparing a reference standard solution by dissolving compound as claimed in claim 1 in solution, preparing a test solution by dissolving a sample of a levosimendan batch in solution, obtaining a HPLC chromatogram of said reference standard solution, obtaining a HPLC chromatogram of said test solution and determining the concentration of compound as claimed in claim 1 in the sample.
The present invention relaes to a pyndazinyl derivative (I) and use as a reference compound in the Jetermination of potentially genotoxic impurities in levosimendan samples. The invention also relates to an analytic method for the determintion of potentially genotoxic impurities in levosimendan samples wherein (I) is used as a reference compound. Levosimendan is a medicanent useful in the treatment of heart failure.

Documents:

« Previous Patent

Next Patent »

Patent Number

206696

Indian Patent Application Number

IN/PCT/2000/00596/KOL

PG Journal Number

19/2007

Publication Date

11-May-2007

Grant Date

10-May-2007

Date of Filing

06-Dec-2000

Name of Patentee

ORION CORPORATION

Applicant Address

ORIONINTIE 1,FINLAND-02200 ESPOO FINLAND

Inventors:

#	Inventor's Name	Inventor's Address
1	BACKSTROM REIJO	POUTAMAENTIE 14 F 68, FIN-00360 HELSINKI FINLAND
2	HEINONEN TUULA	AAMUYONTIE 15B,FIN-02210 ESPOO,
3	HAUTA-AHO TUULA	HIRVIKUJA 3,FIN-01450 VANTAA,

PCT International Classification Number

C07D 307/32

PCT International Application Number

PCT/FI99/00539

PCT International Filing date

1999-06-18

PCT Conventions:

#	PCT Application Number	Date of Convention	Priority Country
1	981428	1998-06-18	Finland